Management holds a conference call to discuss 4D-710 Phase 1/2 AEROW Interim Clinical Data and provide a program update on November 1 at 4:30 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FDMT:
- 4D announces plan to lift clinical hold on Phase 1/2 INGLAXA trial for 4D-310
- Microsoft upgraded, F5 Networks downgraded: Wall Street’s top analyst calls
- 4D Molecular initiated with an Outperform at RBC Capital
- 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
- Cantor starts 4D Molecular at Overweight on ‘compelling’ risk/reward